Chen Hai-xin, Li Han-zhong, Li Hong-jun, Shi Bing-bing, Jin Wei, Cheng Xin-qi
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhonghua Wai Ke Za Zhi. 2007 Mar 15;45(6):412-4.
To evaluate the diagnostic usefulness of serum osteoprotegerin (OPG) in prostate cancer bone metastasis.
Serum osteoprotegerin were measured by ELISA assay in 30 healthy men, 30 patients with benign prostatic hyperplasia, 66 patients with prostate cancer including 36 without bone metastasis (30 with localized cancer, 6 with lymph node metastasis) and 30 with bone metastasis. The results associated with clinical data were calculated statistically.
Serum osteoprotegerin were significantly increased in patients with bone metastasis compared with others (P<0.001). OPG level had a positive correlation with either prostate specific antigen (PSA) or Alkaline phosphatase (ALP) level (r=0.427, 0.277; P<0.001); and a positive correlation with either Gleason score or grade (r=0.427, 0.277; P<0.001). ROC analysis proved that OPG had better diagnostic accuracy than ALP for detecting bone metastasis in prostate cancer.
Serum osteoprotegerin could be used as a marker for diagnosis of bone metastasis in prostate cancer.
评估血清骨保护素（OPG）在前列腺癌骨转移诊断中的应用价值。
采用酶联免疫吸附测定法（ELISA）检测30名健康男性、30例良性前列腺增生患者、66例前列腺癌患者（其中36例无骨转移，包括30例局限性癌患者和6例淋巴结转移患者，30例有骨转移）的血清骨保护素水平。对所得结果与临床数据进行统计学分析。
与其他患者相比，骨转移患者的血清骨保护素水平显著升高（P<0.001）。OPG水平与前列腺特异性抗原（PSA）或碱性磷酸酶（ALP）水平呈正相关（r=0.427，0.277；P<0.001）；与Gleason评分或分级呈正相关（r=0.427，0.277；P<0.001）。ROC分析表明，在检测前列腺癌骨转移方面，OPG的诊断准确性优于ALP。
血清骨保护素可作为前列腺癌骨转移的诊断标志物。
